RCT | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel.
27 Oct, 2022 | 12:23h | UTCContinuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study – The Lancet Oncology (link to abstract – $ for full-text)